
Transforming Oncology
Liquid biopsies provide more therapy options for more patients
Hedera Dx’s liquid biopsy solution will radically streamline tumor profiling, enabling hospital labs to run clinically actionable liquid biopsies in-house.
However, adoption is difficult and reporting is time consuming with existing liquid biopsy solutions
IVD compliance, privacy infrastructure, and validation are challenging to achieve, and even if these obstacles are overcome, existing software workflows are inefficient to run and lack essential features.





liquid biopsy solution will expand treatment options for patients — without the hurdles
Our solution integrates swiftly into your existing laboratory setting with unrivaled simplicity.
How it works
A radically streamlined biopsy process
Blood draw
If a physician determines that a liquid biopsy is needed to find the best treatment option for their patient, a simple blood draw is ordered.

Sequencing
After the patient’s blood sample is sent to the lab, ctDNA is extracted from the plasma and sequenced.

Clinical report
Using our platform, a report is generated that matches EMA-approved therapies to the patient’s tumor ctDNA sequence.

Therapy options
The physician and the patient discuss the report results and determine the best path forward for treatment.

Clinical applications of ctDNA-based liquid biopsies for patients with cancer are broad
Hedera Dx will be launching its first solution for biomarkers-guided treatment selection in advanced disease.
.png)
About
We’re united by a vision to make liquid biopsies globally accessible for patients
1 in 3 people will be diagnosed with cancer during their lifetime. Hedera Dx was born to provide life-saving information for cancer patients when it matters most.

Tommi Lehtonen
CEO, Co-founder

Damien Lapray
CCO, Co-founder, PhD

Christian Meisel
CMO, Co-founder, MD PhD

Valentin Matillon
CFO

Kaarlo Haikonen
Director Engineering & Product

Sanga Mitra Boppudi
Director Assay Development, PhD

Thomas Vetterli
Director Bioinformatics & ML